LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE)
Agency
National Institutes of Health
Posted
Sep 24, 2026
Due Date
Oct 18, 2027
Description
<p>The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission through the LeverAging StraTegies to Maximize ImpLementation and Effectiveness for HIV (LAST MILE) program. This program will encourage collaborations to perform effectiveness trials that incorporate implementation in real-world settings. Examples include combined efficacy-effectiveness trials, pragmatic trials, and hybrid effectiveness-implementation studies. The intent is to bridge findings from traditional clinical trials to real-world implementation. The work will focus on populations across various points of care for prevention or treatment of HIV and its associated coinfections and comorbidities occurring in any age group. The goal of this program is to advance cross-cutting areas of HIV research, including clinical, behavioral and social sciences, epidemiology, and implementation science. This program aligns with the NIH mission to implement advances in HIV/AIDS research. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. </p>
AI Summary
Agency: National Institutes of Health
Details
- Notice ID
- 363948
- Solicitation Number
- RFA-AI-28-015
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
- Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care (RP1- Clinical Trial Optional)
National Institutes of Health
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Scientific Data Research Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health